The biomedicine and health sector is in a good place right now, as we explain on the page about Catalonia on this website, as it already has an innovative ecosystem, with solid projects and global recognition. Nevertheless, biotech companies need new funding to see results from their research and license candidates to the pharmaceutical industry to manufacture drugs and for these to reach patients. Now is when the return on investment gets interesting.
Foreign investment in Catalonia rose 35% in 2014. According to consultancy firm EY, Barcelona is one of the top 10 most attractive cities in Europe for investing and the European capital with the most jobs created from foreign investment.
Apart from private funding, Catalonia will receive investment of 868.4 million euros through 2020 from the European Regional Development Fund (ERDF), including the Smart Specialisation Strategy RIS3CAT, which is 68.1% more than the amount received under the 7th Framework Programme (2007-2013).
15 January 2019
As Josep Lluís Falcó, founder and CEO of Genesis Biomed, explains “we have shown our commitment to projects in early phases, providing our investment and know-how in order to add value to these projects”.
During 2019, Genesis Ventures aims to invest in 10 more projects or companies to complete its €1.2 million investment fund. The tickets vary between €50,000 to €100,000 per investment.
Genesis Biomed is ...
8 January 2019
GlyCardial Diagnostics have received €1.9 million of the SME Instrument phase II funding, in the framework of H2020 programme, to advance in the development of its novel test for the early detection of cardiac ischemia.
"So amazing to have it approved in our first trial. It is highly motivating to see that the EU trusts in our project as much as we do" says Dr Judit Cubedo, CEO at Glycardial.
23 December 2018
Specifically, the clinical stage pharmaceutical company will initiate the Phase I clinical trial of LPT99, its lead investigational drug candidate targeting prevention and treatment of hearing loss.
Spiral was launched in early 2016 by Hugo Peris and is headquartered in the San Francisco Bay Area. Its R&D lab is located in Barcelona. Peris is a board member of Salvat.
Photo: Hugo Peris, founder and CEO of Spiral ...
11 December 2018
RheoDx, a CataloniaBio & HealthTech member, has opened a round of investment to raise €350,000 on the Capital Cell crowdfunding platform. The funds will go to finish technical development of a portable medical device that improves monitoring of patients with haematological diseases (anaemia, liquid cancer, clotting disorders, etc.).
This medical device can detect anomalies in blood cells immediately and affordably, from just one drop of blood. It is a patented technology that came out of research led by professor Aurora Hernández-Machado with Centre de Recerca Matemàtica.
RheoDx was created in 2018 by Oliver Balcells, CEO; Samantha López ...
11 December 2018
This round is bridge funding towards a round to raise between €3 million and €5 million in venture capital to complete phase II clinical trials on the drug ABTL0812 for lung and endometrial cancer in Spain and France.
ABTL0812 is administered in combination with chemotherapy as a first-line therapy and maintenance therapy.
Both Ability Pharma and Capital Cell are members of CataloniaBio & HealthTech.
Photo: Carles Domènech, CEO of ...
13 November 2018
FreeOx Biotech, a spin-out of Hospital Clinic Barcelona-IDIBAPS created in 2017 that is developing a new class of neuroprotective drugs, has closed its first round of funding with €500,000 from private investors Montserrat Esteve and Francisco Javier Alsina.
The biotech member of CataloniaBio & HealthTech has two highly promising molecules in its pipeline to treat stroke and other diseases of the central nervous system (CNS): Ox-01 and Ox-02.
With this funding, they will carry out formulation and preclinical trials with in vivo testing on Ox-02. Also, “it will allow us to prepare to start phase III clinical ...
12 November 2018
iVascular, a CataloniaBio & HealthTech member, has acquired 10% of the shares of the American start-up NaviGate Cardiac Structures for €8,7 million. With this purchase, iVascular becomes part of the Board of Directors of the Navigate.
The agreement between both companies, contemplates the joint development of a new product: the tricuspid valve with percutaneous access. Clinical studies are currently underway in the United States and Europe to analyze the efficacy and safety of this valve, that is estimated to be ready for clinical application by 2020.
iVascular has its headquarters in Sant Vicenç dels Horts (Barcelona).
29 October 2018
Oryzon Genomics, a CataloniaBio & HealthTech member, announced the successful closure of the subscription of a capital increase of 13 million euros through ordinary shares. The offering included corporate investors specialized in healthcare and life sciences from the USA and Europe.
On the other hand, the biopharmaceutical company started the inclusion of the first patient in a Phase IIa clinical trial with Iadademstat (ORY-1001) in elderly Acute Myeloid Leukemia (AML). The study named ALICE (AML trial with LSD1i in Combination with azacitidine in the Elderly) is conducted at two Spanish hospitals, La Fe in Valencia and Vall d'Hebron in Barcelona ...
11 October 2018
Alta Life Sciences, the fund led by Guy Nohra, Montserrat Vendrell, Miguel Valls and Scott Moonly and a CataloniaBio & HealthTech member, has led a €3-million round of investment in Mediktor. The round also included Dutch fund Castel Capital and French Naos Capital Partners.
Mediktor is a symptom assessment software launched as a free app in 2014. Over this time, it has done more than 2 million evaluations of symptoms in 150 countries and created a database that can recognise roughly 750 diseases, covering 90% of the cases seen in emergency and primary care. Recently, Mediktor has collaborated with Hospital ...
26 September 2018
Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases member of CataloniaBio & HealthTech, today announces the completion of a Series B funding round of €21.3 million, the most important in the Catalan biotechnology sector so far this year.
The funding round was led by Fund+, joined by SRIW, SFPI-FPIM and Sambrinvest, in addition to all Series A investors (Ysios Capital, Kurma Partners, Roche Venture Fund, Idinvest Partners, Chiesi Ventures, Caixa Capital Risc and HealthEquity).
“The proceeds of the round will allow the company to demonstrate the potential of MIN-102 in new indications,” ...